Literature DB >> 22578942

Two hundred and eleven cases of Candida osteomyelitis: 17 case reports and a review of the literature.

Amy K Slenker1, Scott W Keith, David L Horn.   

Abstract

Candida osteomyelitis is a rare infection. We present 17 cases of Candida osteomyelitis from our institution and review 194 patients from the literature. The median age of patients was 57 ± 22 years (range, 18-90 years) with 68% male. Comorbidities associated with this infection include prior surgery (62%), broad-spectrum antibiotics (40%), central venous catheter insertion (19%), and immunosuppression (17%). The most common infecting species were Candida albicans (69%), Candida tropicalis (15%), and Candida glabrata (8%). Most initial antifungal regimens included amphotericin B (59%); however, fluconazole is increasingly being utilized for treatment of this infection (26%). Echinocandins were used infrequently (4%). Median length of treatment was 3 ± 4.5 months (mean, 4.2 months; range, 18 days to 36 months). The overall success rate of therapy was 91%, with 75% of patients cured by 6 months. The crude mortality rate was 12% with an attributable mortality rate of 6%.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22578942     DOI: 10.1016/j.diagmicrobio.2012.02.004

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  21 in total

1.  Candida albicans osteomyelitis as a cause of chest pain and visual loss.

Authors:  Rita Magano; Joana Cortez; Evelise Ramos; Luís Trindade
Journal:  BMJ Case Rep       Date:  2015-10-16

2.  Treatment and outcomes of Candida osteomyelitis: review of 53 cases from the PATH Alliance® registry.

Authors:  D Neofytos; S Huprikar; A Reboli; M Schuster; N Azie; B Franks; D Horn
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-08-02       Impact factor: 3.267

Review 3.  Nanostructured platforms for the sustained and local delivery of antibiotics in the treatment of osteomyelitis.

Authors:  Vuk Uskokovic
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  2015       Impact factor: 4.889

4.  Delayed presentation of Candidal Vertebral Osteomyelitis following penetrating spinal injury.

Authors:  S Dilip Chand Raja; Kanna Rishi Mugesh; Shetty Ajoy Prasad; S Rajasekaran
Journal:  J Clin Orthop Trauma       Date:  2019-02-23

Review 5.  Bone and joint infections caused by mucormycetes: A challenging osteoarticular mycosis of the twenty-first century.

Authors:  Saad J Taj-Aldeen; Maria N Gamaletsou; Blandine Rammaert; Nikolaos V Sipsas; Valerie Zeller; Emmanuel Roilides; Dimitrios P Kontoyiannis; Michael Henry; Vidmantas Petraitis; Brad Moriyama; David W Denning; Olivier Lortholary; Thomas J Walsh
Journal:  Med Mycol       Date:  2017-10-01       Impact factor: 4.076

6.  Epigenetic Modification Mediates the Increase of LAG-3+ T Cells in Chronic Osteomyelitis.

Authors:  Yicun Wang; Jun Wang; Jia Meng; Hui Jiang; Jianning Zhao; Hongbo Qian; Tao Chen
Journal:  Inflammation       Date:  2017-04       Impact factor: 4.092

7.  Candida parapsilosis osteomyelitis.

Authors:  Rekha Lopez; Alistair Robert Hunter; Orla Geoghegan; Elli Demertzi
Journal:  BMJ Case Rep       Date:  2014-10-15

8.  Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Peter G Pappas; Carol A Kauffman; David R Andes; Cornelius J Clancy; Kieren A Marr; Luis Ostrosky-Zeichner; Annette C Reboli; Mindy G Schuster; Jose A Vazquez; Thomas J Walsh; Theoklis E Zaoutis; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2015-12-16       Impact factor: 9.079

9.  Candida albicans Osteochondromyelitis after Gastroesophageal Surgery: Two Case Reports.

Authors:  Abdulwares Meiwandi; Hubert Zirngibl; Ahmet Bozkurt
Journal:  Indian J Plast Surg       Date:  2021-07-05

Review 10.  An Italian consensus for invasive candidiasis management (ITALIC).

Authors:  L Scudeller; C Viscoli; F Menichetti; V del Bono; F Cristini; C Tascini; M Bassetti; P Viale
Journal:  Infection       Date:  2013-11-25       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.